Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Shorted: Short Interest Up 183.4% in September

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 360,790 shares, a growth of 183.4% from the August 31st total of 127,301 shares. Based on an average trading volume of 590,511 shares, the short-interest ratio is currently 0.6 days. Currently, 0.0% of the shares of the company are sold short.

Bayer Aktiengesellschaft Stock Up 1.4%

Bayer Aktiengesellschaft stock opened at $14.32 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04. Bayer Aktiengesellschaft has a one year low of $7.48 and a one year high of $15.23. The company has a 50-day simple moving average of $14.00 and a 200-day simple moving average of $12.44. The firm has a market capitalization of $56.28 billion, a P/E ratio of -28.08, a P/E/G ratio of 2.12 and a beta of 0.56.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.06. The firm had revenue of $12.53 billion for the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current year.

Analysts Set New Price Targets

BAYRY has been the subject of several recent research reports. Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Finally, Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY.

The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics.